|View printer-friendly version|
|Array BioPharma To Report Financial Results For The First Quarter Of Fiscal 2015 On November 4, 2014|
BOULDER, Colo., Oct. 29, 2014 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) will report financial results for the first quarter of fiscal 2015 and hold a conference call to discuss those results on Tuesday, November 4, 2014. Ron Squarer, Chief Executive Officer and Michael Carruthers, Chief Financial Officer will lead the call.
About Array BioPharma Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. Seven Phase 3 studies are in progress, or are planned to begin this year. These programs include the wholly-owned hematology drug, filanesib (ARRY-520) for multiple myeloma and two partnered cancer drugs, selumetinib (AstraZeneca) and binimetinib (MEK162 / Novartis). For more information on Array, please go to www.arraybiopharma.com.
SOURCE Array BioPharma